Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer

NCT05691010 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05691010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05691010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
January 10, 2023
Completion date
January 10, 2027
Enrollment
28 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, endometrial carcinoma, endometrial carcinoma stage iii, stage iii endometrial cancer, stage iii endometrial carcinoma